Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Terry L NgMark Clemons

Abstract

Bone-modifying agents (BMAs) for bone metastases are commonly prescribed for many years even though randomized clinical trials are only 1-2 years in duration. A systematic review on the risk-benefit of BMA use for > 2 years in breast cancer or castrate-resistant prostate cancer was conducted. MEDLINE, Embase, and Cochrane databases were searched (1970-February 2019) for randomized and observational studies, and case series reporting on BMA efficacy (skeletal-related events and quality of life) and toxicity (osteonecrosis of the jaw, renal impairment, hypocalcemia, and atypical femoral fractures) beyond 2 years. Of 2107 citations, 64 studies were identified. Three prospective and 9 retrospective studies were eligible. Data beyond 2 years was limited to subgroup analyses in all studies. Only one study (n = 181) reported skeletal-related event rates based on bisphosphonate exposure, with decreased rates from 27.6% (0-24 months) to 15.5% (> 24 months). None reported on quality of life. All 12 studies (denosumab (n = 948), zoledronate (n = 1036), pamidronate (n = 163), pamidronate-zoledronate (n = 522), ibandronate (n = 118)) reported ≥ 1 toxicity outcome. Seven bisphosphonate studies (n = 1077) and one denosumab study (n = 948) rep...Continue Reading

References

Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aristotle BamiasMeletios A Dimopoulos
Nov 4, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D Aguiar BujandaJ Aguiar Morales
Dec 14, 2006·Clinical Drug Investigation·Martin PecherstorferBengt Bergström
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Feb 20, 2010·Current Pharmaceutical Design·Ingunn Holen, Robert E Coleman
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison T StopeckAda Braun
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Sep 15, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Allan LiptonSusie Jun
Dec 29, 2016·JAMA : the Journal of the American Medical Association·Andrew L HimelsteinCharles L Shapiro
May 28, 2017·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Eiji NakataShozo Osumi
Oct 17, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine Van PoznakBeverly Moy
Feb 9, 2018·BMJ Evidence-based Medicine·Mohammad Hassan MuradFateh Bazerbachi
Oct 23, 2018·The New England Journal of Medicine·Nicholas C TurnerMassimo Cristofanilli
Jun 6, 2019·The New England Journal of Medicine·Seock-Ah ImDebu Tripathy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M Chavez Mac GregorS H Giordano
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Mashari AlZahraniTerry L Ng
Journal of Cancer Research and Therapeutics
Naveed Hassan AkhtarAli Arslan Aftab Ahmed
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Christina BilliasRebecca Schorr
© 2022 Meta ULC. All rights reserved